- Interim phase 1/2 results for Inovio Pharmaceuticals' ( NASDAQ: INO ) INO-3107 showed a statistically significant improvement in the number of surgical interventions needed to control papilloma growth.
- The candidate is under investigation for HPV 6 and HPV 11-associated recurrent respiratory papillomatosis.
- Data showed that there was a median decrease of three surgical interventions. Also, 16 of 21 participants had fewer surgical interventions in the year after receiving INO-3107 compared to number of surgeries in the year prior to the trial.
- Check out why Seeking Alpha contributor Bret Jensen considers Inovio ( INO ) a hold.
For further details see:
Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug